KAYS
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
Jan 12 closing price
Capitalization
24.03M
Intraday BUY SELL Signals
KMDA
Price
$7.96
Change
+$0.08 (+1.02%)
Updated
Jan 14 closing price
Capitalization
459.44M
62 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KAYS vs KMDA

Header iconKAYS vs KMDA Comparison
Open Charts KAYS vs KMDABanner chart's image
Kaya Holdings
Price$0.04
Change-$0.00 (-0.00%)
Volume$2.51K
Capitalization24.03M
Kamada
Price$7.96
Change+$0.08 (+1.02%)
Volume$60.9K
Capitalization459.44M
KAYS vs KMDA Comparison Chart in %
KAYS
Daily Signal:
Gain/Loss:
KMDA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
KAYS vs. KMDA commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KAYS is a Hold and KMDA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (KAYS: $0.04 vs. KMDA: $7.96)
Brand notoriety: KAYS and KMDA are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KAYS: 19% vs. KMDA: 70%
Market capitalization -- KAYS: $24.03M vs. KMDA: $459.44M
KAYS [@Pharmaceuticals: Generic] is valued at $24.03M. KMDA’s [@Pharmaceuticals: Generic] market capitalization is $459.44M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.17B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KAYS’s FA Score shows that 1 FA rating(s) are green whileKMDA’s FA Score has 0 green FA rating(s).

  • KAYS’s FA Score: 1 green, 4 red.
  • KMDA’s FA Score: 0 green, 5 red.
According to our system of comparison, KAYS is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KAYS’s TA Score shows that 4 TA indicator(s) are bullish while KMDA’s TA Score has 6 bullish TA indicator(s).

  • KAYS’s TA Score: 4 bullish, 3 bearish.
  • KMDA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, KMDA is a better buy in the short-term than KAYS.

Price Growth

KAYS (@Pharmaceuticals: Generic) experienced а -21.35% price change this week, while KMDA (@Pharmaceuticals: Generic) price change was +1.27% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.60%. For the same industry, the average monthly price growth was +8.77%, and the average quarterly price growth was +19.20%.

Reported Earning Dates

KMDA is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.60% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KMDA($459M) has a higher market cap than KAYS($24M). KMDA has higher P/E ratio than KAYS: KMDA (22.74) vs KAYS (3.30). KMDA YTD gains are higher at: 12.748 vs. KAYS (-11.482). KMDA has higher annual earnings (EBITDA): 37.2M vs. KAYS (-10.44M). KMDA has more cash in the bank: 72M vs. KAYS (26.1K). KAYS has less debt than KMDA: KAYS (580K) vs KMDA (11.5M). KMDA has higher revenues than KAYS: KMDA (175M) vs KAYS (26.7K).
KAYSKMDAKAYS / KMDA
Capitalization24M459M5%
EBITDA-10.44M37.2M-28%
Gain YTD-11.48212.748-90%
P/E Ratio3.3022.7415%
Revenue26.7K175M0%
Total Cash26.1K72M0%
Total Debt580K11.5M5%
FUNDAMENTALS RATINGS
KAYS vs KMDA: Fundamental Ratings
KAYS
KMDA
OUTLOOK RATING
1..100
826
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
10072
SMR RATING
1..100
10077
PRICE GROWTH RATING
1..100
6345
P/E GROWTH RATING
1..100
172
SEASONALITY SCORE
1..100
9021

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KAYS's Valuation (57) in the null industry is in the same range as KMDA (75) in the Biotechnology industry. This means that KAYS’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as KAYS (100) in the null industry. This means that KMDA’s stock grew similarly to KAYS’s over the last 12 months.

KMDA's SMR Rating (77) in the Biotechnology industry is in the same range as KAYS (100) in the null industry. This means that KMDA’s stock grew similarly to KAYS’s over the last 12 months.

KMDA's Price Growth Rating (45) in the Biotechnology industry is in the same range as KAYS (63) in the null industry. This means that KMDA’s stock grew similarly to KAYS’s over the last 12 months.

KAYS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for KMDA (72) in the Biotechnology industry. This means that KAYS’s stock grew significantly faster than KMDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KAYSKMDA
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
71%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
71%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
68%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
64%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
68%
Advances
ODDS (%)
Bullish Trend 9 days ago
69%
Bullish Trend 4 days ago
65%
Declines
ODDS (%)
N/A
Bearish Trend 14 days ago
65%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
73%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
KAYS
Daily Signal:
Gain/Loss:
KMDA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFWAX30.490.16
+0.53%
Calvert Global Water A
LISOX13.840.06
+0.44%
Lazard International Strategic Eq Open
ASCRX17.240.05
+0.29%
American Century Small Company R
OLVAX22.50N/A
N/A
JPMorgan Large Cap Value A
MGPIX113.88-0.31
-0.27%
ProFunds Mid Cap Growth Inv

KAYS and

Correlation & Price change

A.I.dvisor tells us that KAYS and KMDA have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KAYS and KMDA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KAYS
1D Price
Change %
KAYS100%
N/A
KMDA - KAYS
21%
Poorly correlated
+1.02%
UPC - KAYS
8%
Poorly correlated
+0.45%
SHIEF - KAYS
4%
Poorly correlated
N/A
TRUFF - KAYS
4%
Poorly correlated
+5.78%
IMCC - KAYS
3%
Poorly correlated
+1.43%
More

KMDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KMDA has been loosely correlated with LFCR. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if KMDA jumps, then LFCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
+1.02%
LFCR - KMDA
35%
Loosely correlated
+5.63%
TEVA - KMDA
32%
Poorly correlated
+0.52%
SGIOY - KMDA
27%
Poorly correlated
+1.65%
RDY - KMDA
27%
Poorly correlated
+0.61%
OGI - KMDA
26%
Poorly correlated
-4.73%
More